A pre-results briefing note from the drugmaker has told analysts to expect more of this year's profit growth to arrive in the final three months, with currency and interest costs shaping the earlier quarters.
Ahead of its third-quarter results, GSK (LSE:GSK) has done something many large companies do but few investors read closely: it published an aide memoire. The note, released on 8 October 2026, is a reminder to analysts of the factors that will shape the quarter's numbers. Its most striking message for the FTSE 100 pharmaceutical group is that profit growth for 2026 is weighted towards the fourth quarter.
That does not change the full-year targets. It does mean the third-quarter figures may look less impressive than the annual guidance implies, and that the final quarter will carry more of the load.
What GSK reaffirmed
The full-year guidance, all expressed at constant exchange rates, is:
- Turnover growth of 3–5%, with GSK expecting to land in the upper half of that range;
- Core operating profit growth of 7–9%, also in the upper half;
- Core earnings per share growth of 7–9%, but in the lower half of the range; and
- a dividend of 70p for the year.
The difference between the outlook for operating profit and the outlook for earnings per share is the most revealing detail. Operating profit is expected to grow solidly, near the top of its range, while EPS is expected to grow more slowly, near the bottom. The explanation lies in what happens between those two lines of the income statement.
The interest cost behind the gap
GSK expects net interest costs of about £800m for the year, a figure that includes the financing effect of its acquisition of Nuvalent, which completed on 15 July 2026. Interest costs are deducted after operating profit but before earnings per share are calculated. So when a company borrows to fund a deal, operating profit can rise while EPS grows more slowly, because a larger slice of profit goes on servicing debt.
For illustration, imagine a business with £1,000m of operating profit and £100m of interest costs, leaving £900m before tax. If operating profit grows by 8% to £1,080m but interest costs rise to £150m, the figure before tax becomes £930m, a gain of only about 3.3%. The numbers are hypothetical, but the principle explains why GSK's EPS guidance sits in the lower half of its range while operating profit sits in the upper half.
Because the Nuvalent deal closed in the middle of July, any extra interest cost linked to it would mainly affect the second half of the year rather than the first, which also influences how growth is spread across the quarters.
Why the fourth quarter carries more weight
GSK has indicated that profit growth is weighted to the fourth quarter. Companies can have several reasons for a back-loaded year, such as the timing of product launches, the phasing of costs like development and marketing, and the comparison with the same quarter of the previous year. The aide memoire's emphasis on the fourth quarter suggests that one or more of these factors favours the end of the year.
Currency is a further consideration. GSK expects foreign exchange movements to reduce third-quarter turnover by around 1% when reported in sterling. Because the company reports guidance at constant exchange rates, currency moves do not change the targets themselves, but they do affect the headline numbers that appear in the results. As a group with a large share of sales outside the UK, GSK is sensitive to how sterling moves against other currencies. Sterling ended Friday at $1.3233 and €1.1818, both slightly firmer on the day.
Constant exchange rate reporting is designed to strip out that noise. It restates the current period's results using the previous period's exchange rates, so that investors can see underlying growth without the distortion caused by currency swings. The approach is useful for judging how the business is trading, but shareholders still receive dividends and see share prices in sterling, so reported figures matter too. The 70p dividend expectation for the year gives income investors a fixed reference point regardless of quarterly phasing.
There was also positive pipeline news during the week. On 6 October, ViiV Healthcare, GSK's HIV business, said its Cabenuva treatment had met its primary endpoint in a study. Two regulatory milestones also sit inside the period that will shape the fourth quarter: US Food and Drug Administration decision dates for bepirovirsen on 26 October and neladalkib on 27 November. Approval decisions do not usually change near-term profit much, since new medicines take time to build sales, but they can shape expectations for future years.
The FTSE 100 rose 1.1% to 10,552.05 on Friday 9 October, finishing the week up 0.9%. Defensive sectors such as pharmaceuticals can be influenced by bond yields, because their relatively steady earnings are often valued in a similar way to income-generating assets. The 10-year gilt yield reached 5.53% intraday on Thursday 8 October, its highest since July 2007, before easing on Friday. Higher bond yields eventually tend to weigh on share prices, and with the FTSE 100's forecast dividend yield of 3.3% now sitting more than two percentage points below the 10-year gilt yield, income-focused shares face stiffer competition from bonds.
Key dates to watch
- Wed 14 October: US CPI for September, relevant for dollar earnings.
- Wed 21 October: UK CPI for September.
- Mon 26 October: FDA decision date for GSK's bepirovirsen.
- Thu 5 November: Bank of England MPC decision and Monetary Policy Report.
- Fri 27 November: FDA decision date for GSK's neladalkib.
The bottom line
GSK's aide memoire reaffirms its 2026 guidance but signals that profit growth will be concentrated in the fourth quarter. The split between core operating profit growth in the upper half of its range and core EPS growth in the lower half reflects about £800m of net interest costs, including the financing of the Nuvalent acquisition. Currency is expected to trim around 1% from third-quarter turnover. Investors may watch how closely the third-quarter results follow this pattern, and whether the fourth quarter delivers the faster growth GSK has pointed to.






Please wait processing your request...